Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16

被引：0
|
作者：
Jacob P. Thyssen
Marjolein de Bruin-Weller
Antonio Costanzo
Susanne Grond
Christopher Schuster
Chunyuan Liu
Maria Jose Rueda
Yun-Fei Chen
Andreas Pinter
Thomas Bieber
机构：
[1] University of Copenhagen,Department of Dermatology, Bispebjerg Hospital
[2] University Medical Center Utrecht,Department of Dermatology and Allergology, National Expertise Center of Atopic Dermatitis
[3] Humanitas University,Dermatology, Department of Biomedical Sciences
[4] Humanitas Research Hospital,Dermatology
[5] Eli Lilly and Company,Department of Dermatology
[6] Medical University of Vienna,Department of Dermatology, Venereology and Allergology
[7] Tigermed-BDM Inc,Department of Dermatology and Allergy
[8] University Hospital Frankfurt,undefined
[9] University Hospital,undefined
[10] Christine Kühne-Center for Allergy Research and Education (CK-CARE),undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Atopic dermatitis; Classification and regression tree analysis; Severe itch;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3574 / 3587
页数：13
相关论文
共 50 条
  • [31] The impact of severity of atopic dermatitis on patient-reported outcomes of adults with moderate-to-severe atopic dermatitis
    Vietri, Jeffrey
    Nyberg, Fredrik
    Varol, Nebibe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB254 - AB254
  • [32] Dupilumab elicits rapid and sustained improvements in itch in adults with moderate-to-severe atopic dermatitis
    Silverberg, J. I.
    Eckert, L.
    Yosipovitch, G.
    Kim, B.
    Simpson, E. L.
    Rossi, A. B.
    Ardeleanu, M.
    Chen, Z.
    Kaur, M.
    Gadkari, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S105 - S105
  • [33] Observational 24-week study to assess clinical response to upadacitinib posttrial in patients with moderate-to-severe atopic dermatitis
    Batalla, Ana
    Suh-Oh, Hae Jin
    Hernandez, Gregorio Carretero
    Miquel-Miquel, Javier
    Botella-Estrada, Rafael
    Martorell-Calatayud, Antonio
    Sanz-Motilva, Virginia
    Figueras-Nart, Ignasi
    Florez, Angeles
    JEADV CLINICAL PRACTICE, 2023, 2 (03): : 571 - 575
  • [34] Dupilumab treatment provides improvements in signs of atopic dermatitis (AD) at week 100 in adult patients with moderate-to-severe AD who did not achieve ≥ 75% reduction in Eczema Area and Severity Index at week 16
    Armstrong, A.
    Blauvelt, A.
    Simpson, E. L.
    Chen, Z.
    Ardeleanu, M.
    Rossi, A. B.
    Tomondy, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E68 - E69
  • [35] Treatment of moderate-to-severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry
    Traidl, Stephan
    Heinrich, Luise
    Siegels, Doreen
    Heratizadeh, Annice
    Kind, Barbara
    Haufe, Eva
    Abraham, Susanne
    Schaefer, Thomas
    Augustin, Matthias
    Harder, Inken
    Pinter, Andreas
    Schaekel, Knut
    Wollenberg, Andreas
    Ertner, Konstantin
    Ramaker-Brunke, Jutta
    Bong, Anne
    Quist, Sven
    Gorriahn-Maiterth, Hannah
    Schenck, Florian
    Sticherling, Michael
    Effendy, Isaak
    Schwarz, Beate
    Handrick, Christiane
    Asmussen, Andrea
    Weidinger, Stephan
    Schmitt, Jochen
    Werfel, Thomas
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024,
  • [36] Dupilumab treatment provides continued improvements in signs and symptoms through week 100 in patients with moderate-to-severe atopic dermatitis who did not achieve ≥75% reduction in eczema area and severity index at week 16
    Armstrong, A. W.
    Blauvelt, A.
    Simpson, E.
    Chen, Z.
    Ardeleanu, M.
    Rossi, A. B.
    Tomondy, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S49 - S49
  • [37] Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study
    Liu, Bo
    Song, Xiaoting
    Liao, Shuanglu
    Luan, Tingting
    Zhao, Zuotao
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2023, 184 (10) : 966 - 974
  • [38] Baseline Serum Biomarkers Do Not Predict Dupilumab Treatment Response in AdultsWith Moderate-to-Severe Atopic Dermatitis
    Weidinger, Stephan
    Beck, Lisa A.
    de Bruin-Weller, Marjolein S.
    Thyssen, Jacob P.
    Kabashima, Kenji
    Guttman-Yassky, Emma
    Akdis, Cezmi A.
    Chen, Zhen
    Levit, Noah A.
    Bastian, Mike
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 101 - 101
  • [39] Baseline serum biomarkers do not predict dupilumab treatment response in adults with moderate-to-severe atopic dermatitis
    Weidinger, Stephan
    Beck, Lisa A.
    de Bruin-Weller, Marjolein S.
    Thyssen, Jacob P.
    Kabashima, Kenji
    Guttman-Yassky, Emma
    Akdis, Cezmi A.
    Chen, Zhen
    Levit, Noah A.
    Bastian, Mike
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [40] Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
    Saporito, Rachael C.
    Cohen, David J.
    CASE REPORTS IN DERMATOLOGY, 2016, 8 (02): : 179 - 184
12345